| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2015 | 3029 | 1.340 |
Why?
|
| Neoplasms | 21 | 2023 | 3053 | 1.230 |
Why?
|
| Neoplasm Metastasis | 19 | 2016 | 1066 | 1.060 |
Why?
|
| Radiotherapy | 6 | 2014 | 321 | 0.670 |
Why?
|
| Prostatic Neoplasms | 9 | 2007 | 1757 | 0.660 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 530 | 0.630 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 2347 | 0.490 |
Why?
|
| Knowledge | 1 | 2014 | 28 | 0.460 |
Why?
|
| Neovascularization, Pathologic | 6 | 2004 | 354 | 0.450 |
Why?
|
| Education, Medical | 2 | 2014 | 244 | 0.440 |
Why?
|
| Models, Theoretical | 3 | 2005 | 491 | 0.420 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 104 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2004 | 863 | 0.400 |
Why?
|
| Lymphatic Metastasis | 8 | 2003 | 500 | 0.390 |
Why?
|
| Humans | 72 | 2023 | 91073 | 0.390 |
Why?
|
| Physician-Patient Relations | 4 | 2007 | 627 | 0.380 |
Why?
|
| Radiation, Ionizing | 4 | 2010 | 124 | 0.360 |
Why?
|
| Radiation Oncology | 3 | 1997 | 122 | 0.340 |
Why?
|
| Human Experimentation | 1 | 2010 | 39 | 0.330 |
Why?
|
| Nucleoside-Diphosphate Kinase | 2 | 2000 | 12 | 0.330 |
Why?
|
| Ethics, Research | 1 | 2010 | 52 | 0.330 |
Why?
|
| Disease-Free Survival | 12 | 2011 | 1169 | 0.320 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2000 | 19 | 0.320 |
Why?
|
| Patient Advocacy | 3 | 2015 | 54 | 0.310 |
Why?
|
| MicroRNAs | 4 | 2015 | 568 | 0.300 |
Why?
|
| Physician's Role | 4 | 2005 | 177 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2005 | 478 | 0.290 |
Why?
|
| Genetic Therapy | 9 | 2008 | 375 | 0.280 |
Why?
|
| Models, Economic | 1 | 2007 | 63 | 0.280 |
Why?
|
| Hematopoiesis | 1 | 2008 | 170 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2005 | 1374 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 163 | 0.260 |
Why?
|
| Decision Making | 3 | 2007 | 675 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2008 | 705 | 0.260 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 763 | 0.260 |
Why?
|
| Prostatectomy | 3 | 2007 | 476 | 0.260 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 308 | 0.250 |
Why?
|
| Androgen Antagonists | 2 | 2005 | 139 | 0.250 |
Why?
|
| Prognosis | 11 | 2005 | 3825 | 0.250 |
Why?
|
| Attitude of Health Personnel | 2 | 2005 | 652 | 0.250 |
Why?
|
| Transcription Factors | 6 | 2004 | 1671 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2003 | 145 | 0.240 |
Why?
|
| Ethics, Medical | 3 | 2000 | 307 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 2 | 1998 | 343 | 0.240 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 977 | 0.230 |
Why?
|
| Attitude to Health | 1 | 2005 | 220 | 0.230 |
Why?
|
| Nitriles | 1 | 2004 | 157 | 0.220 |
Why?
|
| Triazoles | 1 | 2004 | 107 | 0.210 |
Why?
|
| Biomedical Research | 3 | 2014 | 401 | 0.210 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 99 | 0.210 |
Why?
|
| History, 20th Century | 3 | 2010 | 316 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 80 | 0.200 |
Why?
|
| Managed Care Programs | 2 | 2000 | 41 | 0.200 |
Why?
|
| Brachytherapy | 1 | 2003 | 121 | 0.200 |
Why?
|
| Disease Progression | 8 | 2012 | 1493 | 0.190 |
Why?
|
| Melanoma | 2 | 2013 | 475 | 0.190 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 67 | 0.190 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 222 | 0.180 |
Why?
|
| Lymph Nodes | 4 | 2000 | 554 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 1559 | 0.180 |
Why?
|
| Aged | 16 | 2018 | 19574 | 0.180 |
Why?
|
| Carcinoma | 1 | 2003 | 438 | 0.170 |
Why?
|
| Medical Oncology | 2 | 2014 | 390 | 0.170 |
Why?
|
| Female | 31 | 2018 | 47186 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2013 | 1500 | 0.170 |
Why?
|
| Combined Modality Therapy | 9 | 2005 | 1713 | 0.170 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1144 | 0.160 |
Why?
|
| Cadherins | 1 | 2000 | 165 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 603 | 0.160 |
Why?
|
| Radiosurgery | 2 | 2013 | 286 | 0.160 |
Why?
|
| Middle Aged | 16 | 2018 | 26555 | 0.150 |
Why?
|
| Mammography | 2 | 2000 | 470 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2005 | 291 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 135 | 0.150 |
Why?
|
| Immediate-Early Proteins | 4 | 2004 | 164 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2009 | 185 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2000 | 388 | 0.130 |
Why?
|
| Mastectomy | 2 | 2004 | 254 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 1998 | 342 | 0.130 |
Why?
|
| Prescription Fees | 1 | 2015 | 10 | 0.120 |
Why?
|
| Consumer Advocacy | 1 | 1995 | 10 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2416 | 0.120 |
Why?
|
| Health Care Rationing | 1 | 1996 | 83 | 0.120 |
Why?
|
| Microcirculation | 3 | 2000 | 105 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 1996 | 126 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 6847 | 0.120 |
Why?
|
| United States | 7 | 2015 | 7188 | 0.120 |
Why?
|
| Drug Costs | 1 | 2015 | 67 | 0.120 |
Why?
|
| Erectile Dysfunction | 2 | 2007 | 76 | 0.120 |
Why?
|
| Neoplasm Staging | 5 | 2004 | 2022 | 0.110 |
Why?
|
| Patients | 1 | 1995 | 104 | 0.110 |
Why?
|
| Medical Laboratory Science | 1 | 1994 | 7 | 0.110 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2008 | 24 | 0.110 |
Why?
|
| Clinical Medicine | 1 | 1994 | 34 | 0.110 |
Why?
|
| Life Expectancy | 1 | 1994 | 88 | 0.110 |
Why?
|
| Aging | 1 | 1998 | 732 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 1994 | 118 | 0.110 |
Why?
|
| Patient Participation | 1 | 2015 | 227 | 0.110 |
Why?
|
| Urinary Incontinence | 2 | 2007 | 216 | 0.110 |
Why?
|
| Health Care Reform | 1 | 1994 | 85 | 0.100 |
Why?
|
| History, 19th Century | 2 | 2009 | 56 | 0.100 |
Why?
|
| Male | 13 | 2018 | 43249 | 0.100 |
Why?
|
| Adult | 12 | 2018 | 27147 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2004 | 304 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2013 | 8436 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 475 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 441 | 0.090 |
Why?
|
| Age Factors | 3 | 2007 | 1876 | 0.090 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 397 | 0.090 |
Why?
|
| Informed Consent | 2 | 2010 | 277 | 0.090 |
Why?
|
| Animals | 15 | 2016 | 27783 | 0.090 |
Why?
|
| Philosophy, Medical | 2 | 2005 | 17 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 1998 | 982 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 3716 | 0.090 |
Why?
|
| Ohio | 1 | 2010 | 41 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1991 | 169 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2004 | 167 | 0.080 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 7 | 0.080 |
Why?
|
| Biological Evolution | 1 | 1997 | 988 | 0.080 |
Why?
|
| Research Subjects | 1 | 2010 | 73 | 0.080 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.080 |
Why?
|
| Lung | 2 | 2012 | 1310 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2004 | 897 | 0.080 |
Why?
|
| Universities | 1 | 2010 | 148 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2380 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2615 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 1183 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 97 | 0.080 |
Why?
|
| Military Personnel | 1 | 2010 | 93 | 0.080 |
Why?
|
| Survival Rate | 3 | 2012 | 1898 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 82 | 0.070 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 111 | 0.070 |
Why?
|
| Philosophy | 1 | 2007 | 9 | 0.070 |
Why?
|
| Rectal Diseases | 1 | 2007 | 23 | 0.070 |
Why?
|
| Urethral Stricture | 1 | 2007 | 14 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1993 | 608 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2007 | 37 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2004 | 1248 | 0.070 |
Why?
|
| Actuarial Analysis | 2 | 1997 | 66 | 0.070 |
Why?
|
| Mutation | 1 | 2018 | 4203 | 0.070 |
Why?
|
| Time Factors | 4 | 2005 | 5378 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 2480 | 0.060 |
Why?
|
| Fund Raising | 1 | 2005 | 2 | 0.060 |
Why?
|
| Academies and Institutes | 1 | 2006 | 33 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 2002 | 1993 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2003 | 1750 | 0.060 |
Why?
|
| Dermatology | 1 | 2006 | 41 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2000 | 1806 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1465 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2005 | 77 | 0.060 |
Why?
|
| Heterografts | 2 | 2015 | 105 | 0.060 |
Why?
|
| Sample Size | 1 | 2005 | 125 | 0.060 |
Why?
|
| Mastectomy, Radical | 2 | 1995 | 10 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 866 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 464 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 111 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 232 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2007 | 882 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 294 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2550 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 24 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 455 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 570 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 130 | 0.050 |
Why?
|
| Mice | 9 | 2015 | 11993 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 210 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 854 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 4 | 2004 | 57 | 0.050 |
Why?
|
| Lymphedema | 1 | 2003 | 79 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 295 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 2020 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 657 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 187 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 694 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 179 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1049 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2005 | 2345 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1313 | 0.040 |
Why?
|
| Cisplatin | 1 | 2002 | 599 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 94 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2002 | 821 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2001 | 164 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 968 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2000 | 81 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1404 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 1723 | 0.040 |
Why?
|
| Plasminogen | 1 | 1998 | 45 | 0.040 |
Why?
|
| Genetic Vectors | 4 | 2004 | 448 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 160 | 0.040 |
Why?
|
| Research | 2 | 2003 | 252 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1163 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 94 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 78 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1892 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 202 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 538 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 492 | 0.030 |
Why?
|
| Axilla | 1 | 1997 | 104 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 1996 | 45 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1998 | 465 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1996 | 83 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1998 | 164 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 158 | 0.030 |
Why?
|
| Researcher-Subject Relations | 1 | 1996 | 4 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 409 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1996 | 90 | 0.030 |
Why?
|
| Social Responsibility | 1 | 1996 | 57 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1132 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 87 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2001 | 702 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 62 | 0.030 |
Why?
|
| DNA Repair | 1 | 1997 | 363 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 188 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 607 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 89 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 200 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1933 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1995 | 252 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 260 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1996 | 852 | 0.030 |
Why?
|
| Research Design | 2 | 2003 | 594 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1995 | 270 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 316 | 0.030 |
Why?
|
| Social Values | 1 | 1994 | 44 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 590 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 596 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 74 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 395 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1994 | 101 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1995 | 238 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 1995 | 214 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 307 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 606 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 282 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2004 | 349 | 0.020 |
Why?
|
| Social Change | 1 | 1991 | 8 | 0.020 |
Why?
|
| England | 1 | 1991 | 38 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 265 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 81 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 373 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 153 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 270 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 964 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 421 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 1095 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 33 | 0.020 |
Why?
|
| Esophageal Neoplasms | 2 | 2002 | 333 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 44 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 90 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1993 | 538 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 4043 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1991 | 1738 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 476 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1991 | 430 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1295 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 9399 | 0.020 |
Why?
|
| Necrosis | 2 | 1996 | 211 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 471 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2785 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 47 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 94 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1996 | 565 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2004 | 71 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 233 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 988 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 25 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 356 | 0.010 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2003 | 34 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 499 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2000 | 3303 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 391 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 727 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 136 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2000 | 46 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 613 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 93 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 205 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 785 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 124 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 646 | 0.010 |
Why?
|
| Angiostatins | 1 | 1998 | 15 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 296 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 817 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 435 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 572 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2904 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 793 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1935 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1814 | 0.010 |
Why?
|
| Mastadenovirus | 1 | 1995 | 4 | 0.010 |
Why?
|
| Liposomes | 1 | 1995 | 93 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2891 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 95 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 173 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 368 | 0.010 |
Why?
|
| Thrombosis | 1 | 1996 | 312 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3442 | 0.010 |
Why?
|